Petros Pharmaceuticals, Inc.
PTPI· OTC
Filed Aug 14, 2023 · 10-Q · 45 days after period end · 0001410578-23-001921
| Metric | Q2 2023 | Q2 2022 |
|---|---|---|
| Revenue | $1.99M | $4.19M |
| Net Income | -$2.55M | -$1.81M |
| EPS Diluted | -$1.20 | -$0.88 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Petros Pharmaceuticals, Inc. · CIK 1815903 · Engraved from SEC EDGAR
ended Jun 30, 2023 · filed Aug 14, 2023 · 45 d after period end